NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Teneovita Medical under which the Vancouver-based provider will market and distribute Biocept's Target Selector liquid biopsy testing services to hospitals, individual oncology practices, and other cancer centers in Canada.
Additional terms of the deal were not disclosed.
Biocept's Target Selector testing menu includes assays that detect a variety of cancer-associated biomarkers in either circulating tumor cells or circulating cell-free DNA. Most recently, it launched its first test for use in guiding cancer immunotherapies, a PD-L1 protein expression assay performed on CTCs.
Over the last several months Biocept has inked agreements that also make its tests available to patients in three other international markets: Israel, Mexico, and most recently, the Philippines.